High serum S100A8/A9 levels and high cardiovascular complication rate in type 2 diabetics with ultrasonographic low carotid plaque density

Diabetes Research and Clinical Practice

Volumn 97, Issue 1, 2012, Pages 82-90

  Hirata, Ayumu ^a   Kishida, Ken ^a   Nakatsuji, Hideaki ^a   Hiuge Shimizu, Aki ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Adiponectin; S100A8 A9 complex; Vulnerable blood; Vulnerable plaque

Indexed keywords

ADIPONECTIN; CALGRANULIN A; CALGRANULIN B; URIC ACID;

ANTHROPOMETRY; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CAROTID ARTERY; CORONARY ARTERY DISEASE; ECHOGRAPHY; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; RELATIVE PLAQUE DENSITY; ULTRASOUND SCANNER;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CALGRANULIN A; CALGRANULIN B; CAROTID ARTERY DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INFLAMMATION; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; SMOKING; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 84864076149     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.01.026     Document Type: Article

References (40)

1. Libby P., Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002, 8:1257-1262.
2. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003, 169:203-214.
3. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
4. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
5. Ravasi T., Hsu K., Goyette J., Schroder K., Yang Z., Rahimi F., et al. Probing the S100 protein family through genomic and functional analysis. Genomics 2004, 84:10-22.
6. Frosch M., Strey A., Vogl T., Wulffraat N.M., Kuis W., Sunderkötter C., et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43:628-637.
7. Healy A.M., Pickard M.D., Pradhan A.D., Wang Y., Chen Z., Croce K., et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006, 113:2278-2284.
8. Altwegg L.A., Neidhart M., Hersberger M., Müller S., Eberli F.R., Corti R., et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 2007, 28:941-948.
9. Morrow D.A., Wang Y., Croce K., Sakuma M., Sabatine M.S., Gao H., et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 2008, 155:49-55.
10. Miyamoto S., Ueda M., Ikemoto M., Naruko T., Itoh A., Tamaki S., et al. Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable angina. Heart 2008, 94:1002-1007.
11. Ionita M.G., Vink A., Dijke I.E., Laman J.D., Peeters W., van der Kraak P.H., et al. High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 2009, 29:1220-1227.
12. Peng W.H., Jian W.X., Li H.L., Hou L., Wei Y.D., Li W.M., et al. Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol 2011, 10:41.
13. Nacken W., Roth J., Sorg C., Kerkhoff C. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003, 60:569-580.
14. Kerkhoff C., Klempt M., Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim Biophys Acta 1998, 1448:200-211.
15. Odink K., Cerletti N., Brüggen J., Clerc R.G., Tarcsay L., Zwadlo G., et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987, 330:80-82.
16. McCormick M.M., Rahimi F., Bobryshev Y.V., Gaus K., Zreiqat H., Cai H., et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem 2005, 280:41521-41529.
17. Croce K., Gao H., Wang Y., Mooroka T., Sakuma M., Shi C., et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 2009, 120:427-436.
18. Bouzidi F., Doussiere J. Binding of arachidonic acid to myeloid-related proteins (S100A8/A9) enhances phagocytic NADPH oxidase activation. Biochem Biophys Res Commun 2004, 325:1060-1065.
19. Kerkhoff C., Nacken W., Benedyk M., Dagher M.C., Sopalla C., Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J 2005, 19:467-469.
20. Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., van Zoelen M.A., et al. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007, 13:1042-1049.
21. Boyd J.H., Kan B., Roberts H., Wang Y., Walley K.R. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 2008, 102:1239-1246.
22. Hirata A., Kishida K., Hiuge-Shimizu A., Nakatsuji H., Funahashi T., Shimomura I. Qualitative score of systemic arteriosclerosis by vascular ultrasonography as a predictor of coronary artery disease in type 2 diabetes. Atherosclerosis 2011, 219:623-629.
23. Ryo M., Maeda K., Onda T., Katashima M., Okumiya A., Nishida M., et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 2005, 28:451-453.
24. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
25. Nakatsuji H., Kishida K., Funahashi T., Shimomura I. Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes. Atherosclerosis 2010, 212:243-245. Senri Study II Group.
26. Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., et al. Metabolic syndrome. J Atheroscler Thromb 2008, 15:1-5. review.
27. Okauchi Y., Funahashi T., Noguchi M., Ogawa T., Ryo M., Okita K., et al. Absolute value of bioelectrical impedance analysis-measured visceral fat area with obesity-related cardiovascular risk factors in Japanese workers. J Atheroscler Thromb 2010, 17:1237-1245.
28. Peters S.A., Dogan S., Meijer R., Palmer M.K., Grobbee D.E., Crouse J.R., et al. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time. J Atheroscler Thromb 2011, 18:784-795.
29. Handa N., Matsumoto M., Maeda H., Hougaku H., Ogawa S., Fukunaga R., et al. Ultrasonic evaluation of early carotid atherosclerosis. Stroke 1990, 21:1567-1572.
30. Hiuge-Shimizu A., Maeda N., Hirata A., Nakatsuji H., Nakamura K., Okuno A., et al. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. Arterioscler Thromb Vasc Biol 2011, 31:792-799.
31. Catalán V., Gómez-Ambrosi J., Rodríguez A., Ramírez B., Rotellar F., Valentí V., et al. Increased levels of calprotectin in obesity are related to macrophage content. Impact on inflammation and effect of weight loss. Mol Med 2011, 10.2119/molmed.2011.00144.
32. Foell D., Frosch M., Sorg C., Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004, 344:37-51.
33. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. CAPTURE Study Investigators, Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104-1111.
34. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y. Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
35. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
36. Okauchi Y., Kishida K., Funahashi T., Noguchi M., Ogawa T., Ryo M., et al. Changes in serum adiponectin concentrations correlate with changes in BMI waist circumference, and estimated visceral fat area in middle-aged general population. Diabetes Care 2009, 32:e122.
37. Kishida K., Kim K.K., Funahashi T., Matsuzawa Y., Kang H.C., Shimomura I. Relationships between circulating adiponectin levels and fat distribution in obese subjects. J Atheroscler Thromb 2011, 18:592-595.
38. Takemura Y., Walsh K., Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007, 9:238-243.
39. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
40. Eijgelaar W.J., Heeneman S., Daemen M.J. The vulnerable patient: refocusing on the plaque. Thromb Haemost 2009, 102:231-239.